UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis

By I. Stratton, E. Kohner, Stephen J. Aldington, R. Turner, Rury R. Holman, S. Manley, D. Matthews, for theUKPDS Group. Diabetologia, 2001

1,068 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. (2015, neutral): “People with type 1 are not generally overweight although, at least anecdotally, the weight gain associated with insulin therapy may be a reason for poor compliance [21,22].”
The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making (2004, methodology): “For type 2 diabetes patients, risk multipliers for HbA 1c adjustment are taken from the UKPDS 50 publication 62 and for SBP are based on UKPDS 36 64 .”
Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review (2016, background): “The Diabetes Control and Complications Trial (DCCT) and UKPDS were the two landmark clinical trials that showed tight glycaemic control [HbA1c value of 7% or less] could reduce the risk of DR development and progression in T1DM and T2DM patients, respectively.(22,51) InDCCT for T1DM, intensive treat”
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss (2015, background): “Stratton (2001) [51] Population United Kingdom 1216 Type 2 6 41 Not investigated”